7 Market Access Trends
Reshaping Pharma by 2027

Managed Care Organizations and Pharmacy Benefit Managers are doubling down on formulary exclusions, NDC blocks, and step therapy protocols. What is new in 2026 is the velocity and scope: controls once reserved for primary care brands are now applied to specialty and even oncology products at an accelerating pace.

With the IRA’s Maximum Fair Price (MFP) establishing a visible public benchmark, commercial payers now have a powerful reference point to justify tougher negotiations. Even drugs not subject to Medicare negotiation are feeling the downstream effect, payers expect competitive products to match or undercut the negotiated net price to retain preferred formulary placement.

The result by 2027 will be a more granular, state-by-state fragmentation of coverage, slower launch uptake, and a higher premium on pre-launch access strategy. Manufacturers who engage payers 18–24 months before launch and arrive with robust real-world evidence will earn meaningfully better access positions than those who rely on clinical trial data alone.

The IRA’s redesigned Part D benefit cap limiting out-of-pocket costs for Medicare beneficiaries at $2,000 annually beginning in 2025, represents the most significant OOP relief in decades for the Medicare population. Yet for commercially insured patients, the story runs in the opposite direction. High-deductible health plan enrollment continues its rise, and family coverage premiums are projected to approach $25,000 by 2027.

The concept of “financial toxicity” coined in oncology but now applied across therapeutic categories — has entered mainstream political discourse. Patient advocacy organizations are increasingly sophisticated actors, using OOP data and social media to amplify pricing concerns and influencing formulary and coverage decisions that were once purely commercial negotiations.

Manufacturers that forge proactive agreements with payers to establish OOP caps, and invest in patient navigation platforms that simplify the access journey, will build durable commercial advantage. Companies that leave this to co-pay cards alone will face escalating friction and reputational exposure.

ICER, ASCO, NCCN, these frameworks have become routine reference points in formulary decisions, coverage policy, and physician guidance. By 2027, “value” will have fully entered clinical decision-making criteria. The NCCN’s Categories of Preference already incorporate cost as a factor; ACC/AHA guidelines are embedding cost-effectiveness analysis. This is not a future direction, it is today’s emerging standard.

HEOR and market access teams are operating with broader mandates than ever. Payers increasingly demand transparency not just on clinical endpoints, but on real-world performance, budget impact, and comparative effectiveness against standard of care. Organizations that have integrated HEOR, medical affairs, and access strategy from early development will produce the evidence packages required to succeed at launch.

No single framework will dominate. The landscape will remain fragmented, with payer-specific, academic, and policy group frameworks each influencing different segments. The imperative is early, multi-framework engagement not a single value story, but a portfolio of evidence tailored to each audience.

January 1, 2026 marked a definitive shift in U.S. pharmaceutical pricing dynamics. The first ten drugs subject to Medicare’s Maximum Fair Price including Eliquis, Jardiance, Farxiga, and Januvia, saw reductions averaging 38–60% below 2023 list prices. CMS obtained cuts greater than the statutory minimum for all ten drugs. Fifteen more drugs, including Ozempic and Wegovy, are negotiated for 2027 implementation. Part B biologics enter the program in 2028.

The MFP’s most significant commercial impact extends well beyond directly negotiated drugs. Commercial payers now hold a publicly visible pricing benchmark and are using it. Even for products outside Medicare’s scope, the MFP signals what constitutes a “fair price” in any payer conversation. Pharma can no longer position the U.S. as a global price safety net, and global launch sequencing strategies must be rebuilt accordingly.

Pipeline decisions are already shifting. Manufacturers are reassessing investment in small molecules with long market exclusivity relative to biologics, and accelerating biosimilar and generic development timelines. Structuring launches to demonstrate value before negotiation windows open has become a board-level strategic priority.

The CMS Cell and Gene Therapy Access Model, launched in 2025 with 33 state Medicaid programs, represents the first federally facilitated outcomes-based agreements for gene therapies. Under these contracts, insurers pay more when patients achieve clinically meaningful outcomes and less when they do not. The model for sickle cell therapies has become a template for how high-cost, potentially curative therapies can be financed in ways that are sustainable for payers and commercially viable for manufacturers.

Value-based contracting is scaling beyond cell and gene therapy. AI-driven analytics and real-world evidence platforms are reducing two of the historic barriers, data infrastructure and administrative complexity. Industry leaders report moving from pilots to programmatic contracts. The CMS final rule on value-based purchasing arrangements (effective January 2026) has also removed regulatory friction that previously made outcomes-based deals commercially impractical for Medicaid.

That said, early lessons from subscription-style models (e.g., hepatitis C in Louisiana) caution against overestimating what pricing innovation alone can achieve. Structural healthcare delivery barriers require attention alongside contract design. The winners will be manufacturers who invest in the longitudinal data infrastructure that outcomes contracts depend on before launch, not after.

Payers are demanding evidence packages that extend far beyond the Phase III trial. Real-world performance data, comparative effectiveness across diverse patient populations, and long-term durability evidence are now table stakes in formulary negotiations. The organizations best positioned to deliver this are those that began building real-world evidence infrastructure during clinical development not after approval.

AI is fundamentally changing what is possible in health economics and outcomes research. Machine learning models applied to large RWD datasets can identify the patient subpopulations where value is concentrated, model payer-specific budget impacts, and detect early signals of real-world underperformance that would otherwise emerge only in claims data years after launch. AI-powered platforms are also accelerating the previously labor-intensive process of preparing HEOR submissions and value dossiers.

The convergence of AI, RWE, and mandatory price transparency is creating a new standard of evidence-based market access. By 2027, manufacturers without sophisticated RWE generation and AI-enabled access analytics will be at a structural disadvantage in formulary negotiations particularly for specialty and high-cost therapies where the evidence bar is highest.

The global cell and gene therapy market is projected to reach $200 billion by 2034, growing at a CAGR of approximately 36% from its 2026 base of $17.5 billion. The clinical promise is extraordinary. The commercialization complexity is equally extraordinary. CGT launches in 2026 require an estimated $10–50 million in first-year vendor spend, roughly three to five times a conventional specialty biologic launch encompassing FACT-certified treatment centers, cryogenic supply chains, patient scheduling infrastructure, and outcomes-tracking platforms.

Standard cost-effectiveness models are structurally ill-suited to one-time curative therapies. Health economists are increasingly deploying lifetime value models and long-term quality-adjusted life year analyses to contextualize multi-million dollar price points against decades of avoided chronic treatment costs. But payer willingness to pay particularly in Medicaid and commercial remains constrained in ways that outcome data alone cannot overcome.

By 2027, cell and gene therapy manufacturers that have established durable outcomes-based agreement architectures, invested in site activation networks, and built real-world durability data will be positioned to sustain both patient access and commercial returns. Those that rely on list price justification alone face a shrinking window.